New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - certolizumab pegol 200mg - solution for injection - 200 mg - active: certolizumab pegol 200mg excipient: sodium acetate sodium chloride water for injection - cimzia is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients. · combined with mtx in case of either an inadequate response or intolerance to previous therapy with one or more disease-modifying antirheumatic drugs (dmards) or · as monotherapy in case of a contraindication or intolerance to mtx

Bahrain - English - الهيئة الوطنية لتنظيم المهن والخدمات الصحية، مملكة البحرين

wael pharmacy - certolizumab pegol - solution for injection - 200

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

u.c.b., belgium - certolizumab pegol - solution for injection - 200 mg

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

astellas pharama inc. - certolizumab pegol(genetical recombination) - colorless to yellow and limpid to milky solution for injection in autoinjector

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

astellas pharama inc. - certolizumab pegol(genetical recombination) - colorless to yellow and limpid to milky solution for injection in prefilled syringe

Singapore - English - HSA (Health Sciences Authority)

ucb trading (sg) pte. ltd. - certolizumab pegol (cdp870) - injection, solution - 200 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - certolizumab pegol -

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - certolizumab pegol -

United States - English - NLM (National Library of Medicine)

a-s medication solutions - adalimumab (unii: fys6t7f842) (adalimumab - unii:fys6t7f842) - humira is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. humira can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (dmards). humira is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. humira can be used alone or in combination with methotrexate. humira is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. humira can be used alone or in combination with non-biologic dmards. humira is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. humira is indicated for reducing signs and symptoms and indu

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - tocilizumab -